FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029683286> ?p ?o ?g. }

• W2029683286 endingPage "5222" @default.
• W2029683286 startingPage "5215" @default.
• W2029683286 abstract "Abstract Purpose: Fractionated radioimmunotherapy may improve therapeutic outcome by decreasing heterogeneity of the dose delivered to the tumor and by decreasing hematologic toxicity, thereby allowing an increased amount of radionuclide to be administered. Because humanized anti-CD22 epratuzumab can be given repeatedly, a single-center study was conducted to establish the feasibility, safety, optimal dosing, and preliminary efficacy of weekly administrations of 90Y-labeled 1,4,7,10-tetra-azacyclodecane-N,N′,N″,N‴-tetraacetic acid–conjugated epratuzumab. Experimental Design: Cohorts of three to six patients with B-cell lymphoma received 185 MBq/m2 [90Y]epratuzumab with unconjugated epratuzumab (total protein dose 1.5 mg/kg) once weekly for two to four infusions, with [111In]epratuzumab coadministered at first infusion for scintigraphic imaging and dosimetry. Results: Sixteen patients received treatment without significant infusional reactions. The overall objective response rate was 62% (95% confidence interval, 39-86%) in both indolent (75%) and aggressive disease (50%). Complete responses (CR/CRu) occurred in 25% of patients and were durable (event-free survival, 14-41 months). Two patients receiving four infusions had hematologic dose-limiting toxicity. Serum epratuzumab levels increased with each weekly dose. Of 13 patients with tumor cell CD22 expression determined by flow cytometry, seven of eight with strongly positive results had objective responses, versus one of five with negative or weakly positive results (P = 0.032). Conclusions: Radioimmunotherapy with weekly 185 MBq/m2 [90Y]epratuzumab achieved a high objective response rate (62%) across lymphoma subtypes, including durable CRs. The findings that three weekly infusions (555 MBq/m2, total dose) can be administered safely with only minor toxicity, that antibody levels increased during treatment weeks, and that therapeutic response predominantly occurs in patients with unequivocal CD22 tumor expression provide guidance for future studies." @default.
• W2029683286 created "2016-06-24" @default.
• W2029683286 creator A5003890903 @default.
• W2029683286 creator A5005310278 @default.
• W2029683286 creator A5009201915 @default.
• W2029683286 creator A5012218042 @default.
• W2029683286 creator A5013126792 @default.
• W2029683286 creator A5014083764 @default.
• W2029683286 creator A5017141025 @default.
• W2029683286 creator A5031962740 @default.
• W2029683286 creator A5050258103 @default.
• W2029683286 creator A5076381883 @default.
• W2029683286 date "2005-07-15" @default.
• W2029683286 modified "2023-10-10" @default.
• W2029683286 title "Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab" @default.
• W2029683286 cites W1912693401 @default.
• W2029683286 cites W1933173754 @default.
• W2029683286 cites W1969751970 @default.
• W2029683286 cites W1971384116 @default.
• W2029683286 cites W1974078366 @default.
• W2029683286 cites W1974370610 @default.
• W2029683286 cites W2014654561 @default.
• W2029683286 cites W2041197793 @default.
• W2029683286 cites W2043303586 @default.
• W2029683286 cites W2055741560 @default.
• W2029683286 cites W2066610908 @default.
• W2029683286 cites W2084146339 @default.
• W2029683286 cites W2084377890 @default.
• W2029683286 cites W2107466475 @default.
• W2029683286 cites W2107990794 @default.
• W2029683286 cites W2110646221 @default.
• W2029683286 cites W2117663747 @default.
• W2029683286 cites W2124835126 @default.
• W2029683286 cites W2126422041 @default.
• W2029683286 cites W2126539571 @default.
• W2029683286 cites W2164006259 @default.
• W2029683286 cites W2256690185 @default.
• W2029683286 cites W2267583049 @default.
• W2029683286 cites W2320751441 @default.
• W2029683286 cites W4245716889 @default.
• W2029683286 cites W4246970675 @default.
• W2029683286 doi "https://doi.org/10.1158/1078-0432.ccr-05-0172" @default.
• W2029683286 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16033839" @default.
• W2029683286 hasPublicationYear "2005" @default.
• W2029683286 type Work @default.
• W2029683286 sameAs 2029683286 @default.
• W2029683286 citedByCount "101" @default.
• W2029683286 countsByYear W20296832862012 @default.
• W2029683286 countsByYear W20296832862013 @default.
• W2029683286 countsByYear W20296832862014 @default.
• W2029683286 countsByYear W20296832862015 @default.
• W2029683286 countsByYear W20296832862016 @default.
• W2029683286 countsByYear W20296832862017 @default.
• W2029683286 countsByYear W20296832862018 @default.
• W2029683286 countsByYear W20296832862019 @default.
• W2029683286 countsByYear W20296832862020 @default.
• W2029683286 countsByYear W20296832862021 @default.
• W2029683286 countsByYear W20296832862022 @default.
• W2029683286 countsByYear W20296832862023 @default.
• W2029683286 crossrefType "journal-article" @default.
• W2029683286 hasAuthorship W2029683286A5003890903 @default.
• W2029683286 hasAuthorship W2029683286A5005310278 @default.
• W2029683286 hasAuthorship W2029683286A5009201915 @default.
• W2029683286 hasAuthorship W2029683286A5012218042 @default.
• W2029683286 hasAuthorship W2029683286A5013126792 @default.
• W2029683286 hasAuthorship W2029683286A5014083764 @default.
• W2029683286 hasAuthorship W2029683286A5017141025 @default.
• W2029683286 hasAuthorship W2029683286A5031962740 @default.
• W2029683286 hasAuthorship W2029683286A5050258103 @default.
• W2029683286 hasAuthorship W2029683286A5076381883 @default.
• W2029683286 hasBestOaLocation W20296832861 @default.
• W2029683286 hasConcept C111700020 @default.
• W2029683286 hasConcept C126322002 @default.
• W2029683286 hasConcept C143998085 @default.
• W2029683286 hasConcept C159654299 @default.
• W2029683286 hasConcept C18031839 @default.
• W2029683286 hasConcept C203014093 @default.
• W2029683286 hasConcept C2776146153 @default.
• W2029683286 hasConcept C2779338263 @default.
• W2029683286 hasConcept C2989005 @default.
• W2029683286 hasConcept C542903549 @default.
• W2029683286 hasConcept C71924100 @default.
• W2029683286 hasConceptScore W2029683286C111700020 @default.
• W2029683286 hasConceptScore W2029683286C126322002 @default.
• W2029683286 hasConceptScore W2029683286C143998085 @default.
• W2029683286 hasConceptScore W2029683286C159654299 @default.
• W2029683286 hasConceptScore W2029683286C18031839 @default.
• W2029683286 hasConceptScore W2029683286C203014093 @default.
• W2029683286 hasConceptScore W2029683286C2776146153 @default.
• W2029683286 hasConceptScore W2029683286C2779338263 @default.
• W2029683286 hasConceptScore W2029683286C2989005 @default.
• W2029683286 hasConceptScore W2029683286C542903549 @default.
• W2029683286 hasConceptScore W2029683286C71924100 @default.
• W2029683286 hasIssue "14" @default.
• W2029683286 hasLocation W20296832861 @default.
• W2029683286 hasLocation W20296832862 @default.
• W2029683286 hasOpenAccess W2029683286 @default.
• W2029683286 hasPrimaryLocation W20296832861 @default.

• next